Mayo Clinic: Urinary Bladder Neoplasms trials

The registry lists 11 Urinary Bladder Neoplasms studies with Mayo Clinic as lead sponsor. 6 are open to participants now and 1 have results posted.

Early Phase 1 1Phase 1 1Phase 2 4Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersRecruitingNCT07087860Phase 2
• Exploration of HRQOL and Urinary Outcomes Following Partial CystectomyRecruitingNCT06891209
• Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingNCT06764095Phase 4
• In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingNCT06704191Phase 1/2
• Bladder Bank (a Prospective Banking Study)RecruitingNCT06109857
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerCompletedNCT03617913Phase 2Results posted
• Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship StudyActive, not recruitingNCT06350734
• Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision TherapeuticsTerminatedNCT05819827
• Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder CancerCompletedNCT05399004
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1